Globus Medical Inc. Class A Common Stock vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.98 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 12.9× Globus Medical Inc. Class A Common Stock's market cap, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Vanguard Dividend Appreciation Index Fund ETF for 134 Days on average.
| GMED | VIG | |
|---|---|---|
Market Cap | $10.25B | $132.40B |
Volume | 1,108,124 | 1,027,126 |
Sector | Health | — |
52-Week High | $96.82 | $246.61 |
52-Week Low | $58.33 | $210.70 |
Typical Hold Time | 0 Days | 134 Days |
Enterprise Value | $9.76B | — |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
VIG trades at $239.98, showing minimal daily movement with a slight decline of 0.02%. The technical outlook is bullish based on moving averages, though oscillators are neutral. Recent news highlights its focus on dividend growth, with a 7.5% quarterly dividend increase noted by Seeking Alpha on September 27, 2026. The ETF's strategy excludes high-yield stocks to prioritize consistent dividend growers, as reported by The Motley Fool on September 26, 2026.
The outlook for VIG is supported by its historical average annual returns of 10%, but risks include slow dividend growth and competition from higher-yield ETFs. Investor sentiment is mixed, with some analysts favoring its growth profile over immediate income. Key risks involve market volatility and the ETF's strict eligibility criteria limiting yield potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →